Compare Bristol-Myers Squibb Co (BMY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Recursion Pharmaceuticals Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 71.8× Recursion Pharmaceuticals Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BMY | RXRX | |
|---|---|---|
Market Cap | $129.94B | $1.81B |
Sector | Health | Health |
52-Week High | $65.89 | $6.79 |
52-Week Low | $42.60 | $2.84 |
Enterprise Value | $163.92B | $1.33B |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
